A number of other IL‐6 blockers for the treatment of severe COVID‐19 are ongoing, including sirukumab (NCT04380961); clazakizumab (NCT04381052, NCT04494724, NCT04363502, NCT04659772, and NCT04343989); levilimab (NCT04397562); and olokizumab (NCT04380519 and NCT04452474), which may become important drug candidates in the future. Here, IL6 is linked to COVID-19.